Atropos Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs against aging disorders and cancer using its proprietary senescence technology. The firm's novel approach to senescence modulator (senomodulator) discovery organizes around a high-throughput, content phenotypic screening of compound libraries and rational drug combinations. Called FATES (First ATRX-based Therapeutics Elucidating Senescence), the proprietary technology platform is designed to take advantage of the earliest known molecular marker to show commitment to the irreversible senescence pathway after transient growth arrest. The company is currently conducting preclinical lead selection studies to establish efficacy and safety in in vitro and screening animal models and to support moving into IND-enabling studies for human clinical studies for disease indications in aging and resistant cancers. The companyalso plans to work on identifying senosuppressor compounds with lower apoptosis and toxicity potential for testing in primary skin and other primary tissues.
